Search Ontology:
ChEBI
omipalisib
- Term ID
- CHEBI:95093
- Synonyms
-
- 2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide
- 2,4-difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide
- 2,4-difluoro-N-{2-methoxy-5-[4-(pyridazin-4-yl)quinolin-6-yl]pyridin-3-yl}benzene-1-sulfonamide
- 2,4-difluoro-N-{2-methoxy-5-[4-(pyridazin-4-yl)quinolin-6-yl]pyridin-3-yl}benzenesulfonamide
- GSK 212
- GSK 2126458
- GSK 458
- GSK-212
- GSK-2126458
- GSK-458
- GSK212
- GSK2126458
- GSK458
- omipalisib
- omipalisibum
- Definition
- A member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors.
- References
-
- CAS:1086062-66-9
- Chemspider:25027388
- DrugBank:DB12703
- KEGG:D10718
- PDBeChem:ZIG
- PMID:21464613
- PMID:22297110
- PMID:22389471
- PMID:24392766
- PMID:24900173
- PMID:25170609
- PMID:25298748
- PMID:25504751
- PMID:25659532
- PMID:26603258
- PMID:26604245
- PMID:26819001
- PMID:27450049
- PMID:28938574
- PMID:29487419
- PMID:29976629
- PMID:30133440
- PMID:30765508
- PMID:31494146
- PMID:32381012
- PMID:32382996
- PMID:32804918
- PMID:33360802
- PMID:33521022
- PMID:34234012
- PMID:34284231
- PMID:34330845
- PMID:34461940
- Ontology
- ChEBI ( EBI )
- is a type of
- has_role
Show All 6 Terms
Show first 5 Terms
Phenotype
Phenotype resulting from omipalisib
Phenotype where environments contain omipalisib
Phenotype modified by environments containing omipalisib
Human Disease Model